A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide RP2D. PLM60 is to administered by multi-cycle intravenous infusion.
Advanced Hepatocellular Carcinoma
DRUG: Liposome-entrapped Mitoxantrone Hydrochloride Injection
Dose-limited toxicity (DLT), To identify the dose-limited toxicity (DLT)., 1year|Maximum tolerated dose (MTD), To identify the maximum tolerated dose (MTD)., 1 year|Recommended Phase II Dose (RP2D), To identify the Recommended Phase II Dose (RP2D), 1 year
Area under the plasma concentration versus time curve (AUC), To preliminarily evaluate the AUC in patients with advanced HCC., 2 years|Peak Plasma Concentration (Cmax), To preliminarily evaluate Cmax in patients with advanced HCC., 2 years|Time of peak plasma concentration (Tmax), To preliminarily evaluate Tmax in patients with advanced HCC., 2 years|Median overall survival (OS), To preliminarily evaluate ORR in patients with advanced HCC., 2 years|Median progression free survival (PFS), To preliminarily evaluate PFS in patients with advanced HCC., 2 years|Overall response rate (ORR), To preliminarily evaluate ORR in patients with advanced HCC., 2 years|Duration of Response (DoR), To preliminarily evaluate DoR in patients with advanced HCC., 2 years
This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide RP2D. PLM60 is to administered by multi-cycle intravenous infusion.